← Leaderboards
Christopher B Umbricht
Johns Hopkins University
$5,202,537
Attributed
$5,202,537
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $583.3K · FY2011–23$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$5,202,537 · 3
By mechanism
R01$4,875,537 · 2
R21$327,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- William George Nelson$34,555,726
- Peter R Rapp$7,647,958
- Elizabeth A. Platz$18,230,919
- Alan Keith Meeker$5,318,574
- David Sidransky$59,922,938
Others in their field
Top investigators on “Sampling”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$522,319,685
- David R. Weir · University Of Michigan At Ann Arbor$421,002,438
- David Heimbrook · Leidos Biomedical Research, Inc.$410,224,927
- Eric S Lander · Whitehead Institute For Biomedical Res$395,613,296
- Richard A Gibbs · Baylor College Of Medicine$356,778,395
Research focus
SamplingTissuesGenome-WideResolutionPerformanceMorbidity - Disease RateEpigenetic ProcessFutureGenomicsMalignant NeoplasmsMethylationCopy Number PolymorphismMinorityMolecularCostDna MethylationEventFormalinCohortBreast DiseasesHigh Throughput AnalysisMalignant Breast NeoplasmCandidate MarkerTissue Sample
Grant awards (13)
Discovery and validation of early molecular breast cancer risk markers in benign breast disease$347,746
R01 · FY2023 · CA · contact PI
Discovery and validation of early molecular breast cancer risk markers in benign breast disease$371,604
R01 · FY2022 · CA · contact PI
Discovery and validation of early molecular breast cancer risk markers in benign breast disease$1
R01 · FY2021 · CA · contact PI
Discovery and validation of early molecular breast cancer risk markers in benign breast disease$522,498
R01 · FY2020 · CA · contact PI
Discovery and validation of early molecular breast cancer risk markers in benign breast disease$542,205
R01 · FY2019 · CA · contact PI
Discovery and validation of early molecular breast cancer risk markers in benign breast disease$526,029
R01 · FY2018 · CA · contact PI
Multicenter Genetic, Epigenetic & Expression Analysis of DCIS outcome predictors$348,446
R01 · FY2015 · CA · contact PI
Multicenter Genetic, Epigenetic & Expression Analysis of DCIS outcome predictors$486,308
R01 · FY2014 · CA · contact PI
Multicenter Genetic, Epigenetic & Expression Analysis of DCIS outcome predictors$577,702
R01 · FY2013 · CA · contact PI
Multicenter Genetic, Epigenetic & Expression Analysis of DCIS outcome predictors$583,283
R01 · FY2012 · CA · contact PI
Multicenter Genetic, Epigenetic & Expression Analysis of DCIS outcome predictors$569,715
R01 · FY2011 · CA · contact PI
Fixation of breast and prostate cancer tissue$163,500
R21 · FY2003 · CA
Fixation of breast and prostate cancer tissue$163,500
R21 · FY2002 · CA